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Abstract 
Histopathology is a reflection of the molecular changes and provides prognostic phenotypes 
representing the disease progression. In this study, we introduced feature scores generated from 
hematoxylin and eosin histology images based on deep learning (DL) models developed for 
prostate pathology. We demonstrated that these feature scores were significantly prognostic for 
time to event endpoints (biochemical recurrence and cancer-specific survival) and had 
simultaneously molecular biologic associations to relevant genomic alterations and molecular 
subtypes using already trained DL models that were not exposed to the datasets of the current 
study. Further, we discussed the potential of such feature scores to improve the current tumor 
grading system and the challenges that are associated with tumor heterogeneity and the 
development of prognostic models from histology images. Our findings uncover the potential of 
feature scores from histology images as digital biomarkers in precision medicine and as an 
expanding utility for digital pathology. 
Introduction 
Histopathology studies the morphological and structural changes of tissues caused by diseases 
and plays an essential role in tumor diagnosis and malignancy grading. The structural and 
morphological information from microenvironment and the epithelial components has shown to 
be essential for tumor definition and developing the malignancy grading system. A notable 
example for this is the Gleason grading system for prostate cancer. The Gleason grading system 
was first introduced by Gleason D.F., who initially defined five histopathological patterns 
according the microenvironment structures and epithelial components of the prostatic glands 1. 
Gleason score is a well-validated prognostic parameter for survival outcomes and widely used in 
clinical decision making for prostate cancer cases 2,3. Further, Gleason score has shown to be 
associated with genomic alterations frequently seen in prostate cancer 4,5.  Since its first 
introduction, the Gleason score has experienced several modifications in definition of Gleason 
patterns to improve the grading accuracy and the interobserver reliability 6. Further, the Gleason 
score system was refined to the current Gleason grading system that includes 5 prognostic 
subgroups 7. However, the Gleason grading system still inherits the major limitations of the 
previous versions of the Gleason score system that are associated with interobserver variation 
and criticized for not considering the nuclear morphology and the stroma component 3,8. 
Therefore, other alternative grading systems like HELPAP score and the McKenney’s malignancy 
grading system have been introduced to tackle these limitations; Helpap score is based on the 
glandular differentiation and the nuclear atypia of prostate cancer 9 and seems to improve the 
grading accuracy in low-grade prostate cancer 10. McKenney et al introduced a complex 
histological grading system that considered the stroma patterns among other histological 
patterns 11;  his work revealed that the reactive stromal patterns in prostate cancer “stromagenic 
cancer” are significantly predictive for biochemical recurrence of prostate cancer11. From these 
observations, histopathology is primarily working on determining phenotypic features that are 
prognostic and/or a reflection of the disease biology. Therefore, understanding the development 
history of the current malignancy system is crucial to design and extract prognostic and 
biologically significant features from histology images using computational solutions. Several 
approaches are available to extract features from histology images including handcrafted feature 
extraction and the non-handcrafted feature extraction 12. The deep learning is one of the 
advanced machine learning approaches and enables the construction of complex neural 
networks for solving the image classification problem 13. The convolutional neural network is part 
of the deep learning and tackles the classification problems with multiple convolutional layers, 
where deep layers act as a set of non-handcrafted feature extractors that are quite generic and, 
to some extent, independent of any specific classification task 12,14. Thousand features can be 
generated from images and utilized for regression analyses 15,16. However, the internal validation 
of logistic or cox regression models is restricted by the number of events and the parameters 
being considered 17. Harrel et al and Peduzzi et al suggested that the ratios of events per variable 
(EPV)  should be at least 10 to maintain the validity of the logistic or cox regression model 18,19.  
Given this, the results from previous studies showing lower EPV without any adjustment 
measurements for cofounders (e.g., the propensity score matching) are therefore limited 17,20. 
The current study overcomes the limitations of previous works and provides novel feature scores 
that are prognostic and have biological significance. For the simplicity, the current study will 
evaluate the feature scores from Hematoxylin and Eosin (H&E) stained histology images that are 
related to prostate pathology. These feature scores are based on feature maps generated by 
customized convolutional neural network (CNN) models. The CNN models for prostate pathology 
were derived from PlexusNet21 and Visual Geometry Group (VGG)22, and developed on datasets 
independent from the dataset of the current study. The biological significance of feature scores 
was determined by identifying their associations with the genomic alterations described by the 
TCGA (The Cancer Genome Atlas) study for prostate cancer 4. The logistic regression analyses for 
the relevant associations were validated by applying the 1000-samples bootstrapping. Further, 
we developed and internally validated the cox regression analyses for biochemical recurrence by 
meeting the EPV requirement and applying the 1000-samples bootstrapping on TCGA-PRAD 
dataset. The cox regression model was then tested on the McNeal’s dataset that has a median 
follow-up of 9 years for cancer-specific survival to verify the prognostic values of these features 
on the unseen dataset for the unseen survival endpoint (i.e. prostate cancer-related death). 
Results 
 
Association between Feature scores and genomic alterations 
After the feature scores were calculated from feature maps of the tumor lesions generated by 
detection models for high-grade prostatic intraepithelial neoplasia (HGPIN), Gleason pattern 3 
(GP3) and 4 (GP4), cribriform (CR) and ductal morphology (DA), we tested their association with 
the genomic alterations, clusters and subtypes introduced by the TCGA study for prostate cancer 
4. For more clarification, we assigned each feature score to an alphabet to emphasize that these 
feature scores were calculated from different models (H: HGPIN model; G: GP3 model; P: GP4 
model, D: DA model; C: Cribriform model). These feature maps or scores don’t represent the 
findings for which the models were trained and are results of feature extraction process in the 
deep layers. Supplement file 1 provides the cohort characteristic for genomic evaluation. 
Supplement file 2 lists the screening results of the data distribution for feature scores and 
Gleason scores in 43 genomic alterations as well as the 5 subtypes and clusters mentioned in the 
TCGA study 4. Only significant feature scores were considered for an associative analysis in each 
genomic variable. Figures 1 and 3 illustrate results of histogenomic analyses that show the 
feature scores in two patients groups having distinct genomic alterations. Supplement Table 1 
provides the results of descriptive analyses for H, feature scores and Gleason grading (GG) after 
stratifying by associative genomic alterations (i.e., AR splice variant 7 status, the presence of TP53 
hetero loss, and the presence of the high SPINK1 expression). The Gleason score or grading was 
determined at case level by pathologists from the TCGA study. 
Supplement Table 2 provides the results of univariate and multivariate regression analyses for 
features scores (H,G,D, P and C), Gleason scores, and their associated genomic alterations (i.e., 
AR protein expression level, AR score, AR RNA expression level, AR splice variant 7, fraction of 
altered genome, the presence status of TP53 heterozygous loss  , and the existence of high 
SPINK1 expression). The following sections will present the genomic alterations and subtypes 
that were associated with feature scores. Since the H feature score was significant for many 
genomic alterations, we performed the t-Distributed Stochastic Neighbor Embedding (t-SNE) to 
visualize the distribution of these feature scores in connection with the related H&E histology 
images (Figure 2). Thereafter, we clustered the feature scores into 2 clusters using the K-mean 
clustering. Here, we evaluated 28 indices for clustering and applied the majority vote approach 
to determine the optimal cluster number for the feature scores using the R package “NbClust” 23. 
Then, we evaluated the common prostate cancer morphologies of the histology images that are 
located in the centroid area of these clusters (diameter: 0.5 unit) and provided representative 
spots form these images in Figure 2. Finally, we evaluated the frequency of AR SV7 status in these 
clusters using the Fisher Exact test which showed that the distribution of AR SV7 status is 
significantly different between these clusters. 
  
Figure 1: The pirates plots and the diagrams for the area under curve (AUC) of the receiver operating characteristic curve for 
features scores generated by models trained for the detection of HGPIN -H feature score- (A,B) and GP3 (C-F) -G feature score- 
and their assoicated genomic alterations. On the pirate plots (A,C,E), the middle line represents the mean value, the box represents 
the 95% confidence interval, the the colored areas represent the data density. P-values are estimated using the Wilcoxon–Mann–
Whitney test. On the AUC-ROC diagrams, the overall 95% confidence intervals (CI) are given in parentheses. The 95% confidence 
of AUC was calculated by DeLong approach. The turquoise area represents the bootstrapped 95% CI of the sensitivity curves. With 
the exception of SPINK1 (10-times resampling), the 95% CI was calculated after applying resampling 1000-times. 
Blended due to copyright issue. 
 Figure 2 illustrates A) The data visualization of feature scores with a dimension of 1x160 generated by the detection model for 
HGPIN (H feature score) using T-distributed Stochastic Neighbor Embedding (t-SNE) in connection with the corresponding H&E-
stained histology images. The gray circle defines the centroid area (Diameter: 0.5 units). (B) provides representative H&E histology 
images of common prostate cancer morphologies found on some H&E slides, whose feature scores are located inside the gray 
circle of each cluster (centroid area). ** denote that all selected cases from cluster 2 have a negative Androgen receptor splice 
variant-7 (AR-SV7) status. A high-resolution version of each snapshot in at 10x is available in the supplement section. 
Blended due to copyright issue. 
Androgen-receptor expression 
The H feature score and the Gleason score were independent predictors for the protein level of 
the Androgen receptor according to the multivariate analysis. The increasing H feature score was 
associated with decrease in the protein level of the androgen receptor [Odds ratio (OR): 0.998; 
95% Confidence Interval (CI): 0.997– 0.999; AIC: -165.34; P=4.13e-05; Spearman correlation 
Coefficient (CC):  -0.294]. Furthermore, the H feature score was an independent predictor for the 
derived numeric feature “AR score” (OR: 0.926; 95% CI: 0.882 – 0.974; AIC: 1284, P= 0.00191; 
Spearman CC: -0.2255), while Gleason score was not (P= 0.71337). In multivariate analysis 
including Gleason score, the G feature score was, in addition to Gleason score, an independent 
predictor for rise in the RNA expression level of the Androgen receptor (OR: 1.004; 95% CI 1.001 
- 1.007; AIC: -171.15; P= 0.02525, Spearman CC:  0.222). 
Androgen-receptor splice variant 7 
The H feature score is predictive for the presence of Androgen-receptor splice variant 7 (AR SV7) 
(OR: 0.967; 95% Cl: 0.944– 0.987; P=0.00305, AIC: 272.8].  In a multivariate regression analysis 
including Gleason score and H feature score, the H feature score was an independent predictor 
for the presence of AR SV7 (P=0.0032), whereas the Gleason score was not (P=0.5733); the mean 
H feature score of AR SV7 cases was 82.1 (95% CI: 79.3 - 85.2) and the cases with absence of AR 
SV7 had a mean H feature score of 90.9 (95% CI: 88.0 - 93.8) (Figure 1A). The AUROC (area under 
received characteristic curve) of the H feature score for the AR SV7 status prediction was 0.633 
(95% CI: 0.557-0.710) as shown in Figure 1B. 
Fraction of altered genome 
In addition to Gleason score, the D and H feature scores were independent predictors of the 
fraction of altered genome (D: P=0.0281, H: P=0.00159) while the G feature score is not 
(P=0.52583) as shown in Supplement Table 2. The spearman correlation coefficient (CC) for the 
D feature score was -0.16 (P=0.01305) and for the H feature score was 0.14 (P=0.03), while the 
Gleason score had the strongest correlation with the fraction of altered genome (Spearman CC: 
0.50; P=4.32e-15). 
TP53 heterozygous loss   
The multivariate analysis revealed that Gleason score was an independent predictor for the 
presence of heterozygous loss (hetero-loss) of the TP53 (P=9.19e-05) whereas the G feature score 
was not predictive for TP53 hetero-loss (P= 0.184). By evaluating the G feature scores by the TP53 
hetero-loss status, the mean G feature score was 38.0 (95% CI: 36.6 - 39.3) for cases with the 
TP53 hetero-loss and 35.9 (95% CI: 34.9 - 37.0) for cases with diploid TP35 gene. By stratifying 
the G feature score according to GG groups, the G feature score was a significant predictor for 
the TP53 hetero-loss only in “the 4+3” GG group [OR: 1.119 (95% CI: 1.027 - 1.234), P= 0.01537, 
AIC: 75] with AUROC of 0.698 (0.598 – 0.838). In cases with the Gleason grade 7b (4+3), the mean 
score of the GP3 features was 39.7 (95% CI: 37.2 - 42.2) for the TP53 hetero loss and 35.1 (95% 
CI: 33.0 - 37.2) for the TP53 diploid. 
SPINK1 Expression 
Multivariate regression analysis including the G feature score and Gleason score showed that the 
G feature score was the only predictive parameter for elevated SPINK1 expression. An increase 
in the G feature score was associated with decreasing probability of the presence of elevated 
SPINK1 expression (OR: 0.906, 95% CI: 0.828-0.978; P=0.0358; AIC: 91; AUROC: 0.686, 95% CI: 
0.560-0.811). The mean G feature score was 32.7 (95% CI: 29.4 - 35.7) for cases with high SPINK1 
expression and 36.8 (95% CI: 35.8 - 37.6) for cases with non-elevated SPINK1 expression. Due to 
the low number of 11 cases with SPINK1 overexpression, we applied 10 times bootstrapping. 
SPOP mutation 
Given that a recent study found that a SPOP mutation can be detected on the basis of histology 
images in prostate cancer 24, we conducted an association analysis and were able to identify  one 
of our feature scores (P feature score) was associated with the SPOP mutation after applying a 
rectifier that considers the negative values and then inverts these values to positive; the 
transformed P feature score was an independent predictor for SPOP mutation (OR: 0.991, 95% 
CI: 0.983-0.998; P=0.0148; AUROC: 0.625, 95% CI: 0.519-0.731; AIC: 177.35) in multivariate 
analysis including Gleason grade. Twenty-eight cases with the SPOP mutation had a mean value 
of 85.2 (95% CI: 66.1-104.3), whereas 223 cases with SPOP negative mutation had a mean value 
of 117.2 (95% CI: 107.4-127.0). 
mRNA clusters 
The TCGA study determined 3 clusters for mRNA expression profiles and we identified an 
association between these clusters and the H and P feature scores. The post-hoc analyses reveal 
that the Gleason scores were significantly higher in cluster 2 compared to cluster 1 (adj. P= 
0.0094657) and 3 (adj. P= 0.0004570). The P feature score in cluster 3 differs significantly from 
that in cluster 1 (adj. P=0.0259211) while no significant difference in the P feature score was 
observed between clusters 2 and 3 (adj. P= 0.141) or clusters 2 and 1 (adj. P= 0.786). In addition, 
the H feature scores were significantly different between cluster 2 and 3 (adj. P= 0.041) and 
between 1 and 3 (adj. P= 0.0690949), although the post-hoc analysis could not determine any 
significant differences in H feature scores between cluster 1 and 2 (adj. P= 0.978). Figure 3 
summarizes the post-hoc analyses between the feature scores, Gleason score and mRNA clusters.  
miRNA clusters 
Six clusters for the miRNA expression profiles were identified by the TCGA study. The post-hoc 
analyses revealed that the Gleason scores were significantly lower in clusters 1 and 2 compared 
to clusters 3-6 (adj. P range between 4.680e-4 and 0.0299005) with an exception between 
clusters 1 and 4 (adj. P= 0.089767) as shown In Figure 3. The P feature score was significantly 
lower in cluster 6 compared to clusters 2, 4, and 5 (adj. P range between 0.0077803 and 
0.0221771). The average P feature score in cluster 6 was comparable to that in cluster 3 (adj. 
P=0.3539039). Cluster 4 had significantly a lower H feature score compared to cluster 5 (adj. P= 
0.093) and 6 (adj. P= 0.031), while the G feature scores were comparable across all clusters (adj. 
P range between 0.1651872 and 0.9999994). 
 Figure 3: An illustrative representation of post-hoc analyses results according to Tukey that evaluated the variation in P and H 
feature scores and Gleason score between miRNA and mRNA clusters defined by the TCGA-PRAD study. A summary of the post-
hoc analysis is also provided for miRNA and mRNA clusters. Adj. P-value: Adjusted P-value according to Tukey. 
Blended due to copyright issue. 
Feature scores as prognostic factors 
Patient characteristics for TCGA and McNeal cohorts are provided in supplement Table 3. 
Seventy-eight cases were excluded from TCGA-PRAD cohorts because of missing follow-up data. 
The median follow-up time for the TCGA-PRAD dataset was 2.57 years whereas the McNeal 
dataset had a median follow-up time of 9 years. In TCGA-PRAD dataset, forty-six patients (12.7%) 
had a biochemical recurrence, whereas 5 patients were died during the 9 years follow-up in the 
McNeal dataset. According to the univariate cox regression analyses, G and C feature scores were 
predictive for biochemical recurrence (BCR) whereas H, P and D were not; when all feature scores 
included in a multivariate cox regression analysis, only H and G were independently predictive 
for BCR (Table 1). By applying the stepwise cox regression analysis, we found that a model 
containing H, G and D feature scores provided the most suitable goodness-of-fit (AIC = 472) and 
were therefore considered for the multivariate cox regression analyses. In multivariate analyses, 
Gleason grading and the G feature score were independent prognostic factors for BCR whereas 
the H and D feature scores were not. We repeated the multivariate analyses after replacing the 
Gleason grading with the tumor stage (pT) and found that the G and H feature scores were 
independent prognostic factors for BCR (Table 1). The likelihood ratio test statistic (distributed 
chi-squared: 28.095, P=1.155e-07) revealed that a model with these three feature scores fits 
significantly better than a model containing the Gleason grading group only.  
We built two cox regression models for BCR prognosis (Table 1) to identify the effect of combining 
GG groups and these feature scores; the first cox regression model considered the three feature 
scores mentioned above; the second cox regression model included, in addition to the previous 
feature scores, the GG groups. The first model achieved a c-index of 0.706 (95% CI: 0.606-0.779). 
The second cox regression model combining Gleason grading and the feature scores achieved a 
higher c-index of 0.748 (95% CI: 0.620-0.821), emphasizing that this combination improves the 
discriminative performance for BCR prognosis. The Schoenfeld residuals was applied to check the 
proportional hazards assumption and showed that the ratio of the hazards for all three feature 
scores is constant over time (Supplement file 1). The linear predictors from each model was 
binarily categorized into two risk groups by applying the mean value of 0.61 as threshold to 
estimate the survival function using the Kaplan-Meier Curves. The KM curve from Figure 4A 
showed that these risk groups determined by the first cox regression model -model A- are 
significantly discriminative (Log-rank P-value<0.0001). In one hand, we found that the low-risk 
group (n=177) achieved a 2-year BCR-free survival rate (PFS) of 97.4 % (95% CI: 94.9 - 100.0%) 
and a 5-year PFS of 88.3 % (95% CI: 80.6 - 96.7%). In another hand, the high-risk group (n=194) 
showed a 2-year PFS of 86.3 % (95% CI: 81.1 - 91.8%) and a 5-year PFS of 66.9 % (95% CI: 54.6 - 
0.82.1%). When the second cox regression model (model A + GG groups) -model B- was applied 
to BCR prognosis, the gap between the two curves for the low-risk and high-risk groups was wider 
emphasizing that the  both groups from model B are more discriminative than those from model 
A (Figure 4B). Additionally, we validated the cox regression model that predicted the cancer-
specific survival of 68 McNeal cases who underwent radical prostatectomy after adjusting the 5-
year cancer-specific survival rate of the cohort close to 94% according to Wight et al 25. After 
stratifying these McNeal cases into to the binary risk groups, the Kaplan-Meier Curve showed 
that these risk groups (Log-rank P-value= 0.0025) are also discriminative for cancer-specific 
survival, although these risk groups were developed for the prognosis of the biochemical 
recurrence as shown in Figure 5. Based on the risk groups defined by model A, no cancer-specific 
death event was registered in the low-risk group (n=43) during a 9-year follow-up after the 
surgical treatment [5-year cancer-specific survival (CSS) rate: 100%], while the high-risk group 
(n=25) showed a 5-year CSS rate of 83.6% (95% CI: 70.2-99.7%)]. According to the risk groups 
defined by Model B, the low-risk group (n=35) also showed a similar cancer-specific survival rate 
of 100% during the 5-years follow-up after the surgical treatment (Figure 5A) while the high-risk 
group (n=30)  had a 5-year CSS rate of 87.6% (95% CI: 76.9-99.8%) (Figure 5B). To note that the 
Gleason grading 7a or 7b didn’t show any significant differences in survival outcome on McNeal 
dataset. Supplement file 3 includes Kaplan Meier Curves for Gleason grading groups on TCGA 
datasets and the adjusted McNeal dataset. It also provides Kaplan Meier Curves for the risk 
groups and Gleason scores for the larger dataset from McNeal dataset (n=125) which reveal that 
the results did not change even after including additional cases. 
Table 1: The univariate and multivariate cox regression analyses. * denote the that that 95% confidence interval was calculated 
by the bias-corrected and accelerated bootstrap method. HR: Hazard ratio; C-index: Concordance index. pT: pathological AJCC 
tumor stage; AIC: Akaike information criterion; EPV: Events per variable. 
 
Blended due to copyright issue. 
 Figure 4 The Kaplan Meier curves for biochemical recurrence-free survival for model A (H, G and D feature scores) and model B 
(H,G and D feature scores, and Gleason grading groups). 
Blended due to copyright issue. 
 Figure 5: The Kaplan Meier curves for 68 cases from the McNeal data set where the cancer-specific survival rate of the cohort 
was adjusted to 94% 5-year cancer-specific survival rate according to the data from Wight et al 25.  
 
Blended due to copyright issue. 
Discussion 
We provide for the first-time feature scores from histology images that are prognostic and have 
simultaneously biological associations. The discovery of these feature scores is confirmed by the 
well-established fact that histopathology is a reflection of cancer biology and tumor progression 
and histopathology is prognostic for the outcome. Further, the current study shows that DL 
models initially developed to determine the tumor precursor and tumor grading generate feature 
maps with relevant information for prognostic and biological associations from “unseen” 
datasets. Our rigorous validation of the feature scores for their prognostic values reveal that 
these feature scores are robust prognostic feature scores even after changing the endpoint from 
the biochemical recurrence (BCR) to cancer-related death. According to the model comparison 
analysis, a cox regression model that combines three feature scores is better fitted to outcome 
prediction than the Gleason grading system. Further, the incorporation of feature scores into the 
Gleason grading system enhances its discriminative accuracy (c-index improvement from 0.706 
to 0.746), highlighting the potential to improve the current Gleason grading system with these 
feature scores. According to the literatures, a previous work showed the feasibility to determine 
specific mutations based on histology images in lung cancer 26. One other study introduced the 
application of genomic data and histology images to predict the outcome in prostate cancer27. 
However, none of the previous studies introduced feature scores from histology images that are 
prognostic and biologically significant at the same time. Moreover, none of the previous studies 
was able to provide such robust prognostic features for prostate cancer. 
Our study evaluated the association between the feature scores and the most relevant genomic 
alterations related to prostate cancers. Here, we found that the feature scores are significantly 
correlated with the androgen receptor at different levels (protein, androgen score, mRNA 
expression and splice variant 7), SPINK1 overexpression and the heterozygous loss of TP53, the 
presence of SPOP mutation and weakly associated with the fraction of altered genome, 
emphasizing that these feature scores are potential digital biomarkers for genomic alterations 
and molecular subtypes of prostate cancer.  
The androgen activity plays a crucial role in prostate cancer pathogenesis and responsible for the 
creation and overexpression of most ETS (erythroblastosis virus E26 transformation-specific) 
fusions in prostate cancer 28,29. Gene fusions involving ETS family transcription factors are found 
in approximately 50% of prostate cancers and are the basis for the molecular subclassification of 
prostate cancer4,30,31. Additionally, the mRNA and miRNA clusters identified by the TCGA research 
team for prostate cancer have shown to be tightly correlated with ETS fusion status4. The 
androgen receptor (AR) is a ligand-dependent transcription activator for the androgenic 
hormones like testosterone or the more potent dihydrotestosterone 32-34. AR regulates the 
normal prostate development and prostate function35-37, as well as the growth and the 
progression of PCa33. Additionally, AR is highly expressed in androgen-dependent and recurrent 
prostate cancer38. The AR splice variant-7 (AR-SV7) is a truncated form of the androgen receptor 
that lacks the ligand-binding domain and is linked to the development of the castration-resistant 
prostate cancer 39,40. The truncated variants of AR are capable of activating AR target genes in 
the absence of androgens 41. Further, the AR-SV7 overexpression in primary prostate cancer has 
been associated with a worse prognosis after radical prostatectomy42.  SPINK1 is serine protease 
inhibitor Kazal-type 1 and generally overexpressed in ETS-fusion-negative PCA and hence 
represent a molecular subtype of PCa4. The overexpression of SPINK1 stimulates the cell 
proliferation and invasion in ETS-fusion–negative PCa43,44 and associated with poor prognosis 
45,46.  The tumor protein p53 (TP53) is one of most studied genes or proteins in cancer research 
and regulates the cell cycle and hence functions as a tumor suppression 47. The alteration of TP53 
leads to compromises cellular cycles inducing apoptosis in DNA damaged cells and consequently 
promotes tumor progression through acquisition of additional genetic alterations48.  Further, the 
TP53 copy number loss in primary tumor of prostate cancer was found to be prognostic for 
recurrence and metastatic events 49. The SPOP gene is another tumor suppressive gene in 
prostate cancer that encodes for the substrate-recognition component of a Cullin3-based E3-
ubiquitin ligase50. Mutations in SPOP represents the most common point mutations in primary 
prostate cancer (6-13%) 4,51, where SPOP-mutated PCa shows the highest transcriptional activity 
of AR52. Further, SPOP mutation drives the tumorigenesis of prostate cancer by affecting the both 
PI3K/mTOR and AR signaling 53. Although the prognostic value of SPOP mutation is unclear, its 
expression level was associated with poor outcome in primary prostate cancer 54. 
The current study has some limitations that warrant mention. First, the current study used a 
prospectively collected retrospective data and therefore inherits the limitations of a 
retrospective study. We aim to initiate a prospective study that would confirm the clinical 
utilization of these feature scores for prognosis and detecting the subtypes. Second, we didn’t 
consider the whole slides of each case and therefore the tumor heterogeneity that may have 
impact the outcome. However, the current study considered using histology images from the 
index lesions to confirm the prognostic value of the feature scores (The largest tumor lesion in 
the prostate) as the tumor grade of the index lesions significantly influences the final tumor grade 
of the patients and has shown to be associated with survival outcome 55,56 .  
 In summary, the current study identified novel feature scores from histology images that have 
associations with molecular subtypes of prostate cancer and show prognostic values. Such 
feature scores can be utilized as digital biomarkers for personalized precision medicine in 
prostate cancer. Such digital biomarkers will moreover facilitate identifying subsets associated 
with worse outcomes or patient groups that may benefit from specific treatment regimens using 
a non-invasive computational algorithm. Further, these feature scores can potentially improve 
the current Gleason grading system as our findings reveal. Nevertheless, further detailed 
evaluation is required to validate the improvement of the Gleason grading system by these 
feature scores. 
Materials and Methods  
For the current study, we examined only DL models that were not trained on the TCGA datasets 
in order to avoid any possible interaction or bias associated with training on the TCGA-PRAD 
dataset from the previous study that introduced different models for prostate pathology. For 
that reason, we considered feature matrices generated by detection models for HGPIN, Gleason 
patterns 3 and 4, and cribriform and ductal morphology. Detection models for inflammation, 
prostate cancer, vessel and nerve, and Gleason pattern 5 were trained on datasets having TCGA-
PRAD images and therefore excluded from the current study. For each whole-slide H&E-stained 
diagnostic image, the feature matrices were derived from tumor areas and stored in the cMDX 
file. For simplicity, we will describe the calculation steps of a single feature score. First, we 
computed the median value of each column of the feature matrix, that cover all patch images 
from the tumor regions of a single WS image. Then, the column-wise median values were added 
to a single value called the feature score of the particular model that generated the feature 
matrix. The reason of considering the median value is that the median value is less affected or 
distorted by outliers. To simplify the description of the feature scores, we assigned each feature 
score to an alphabet to emphasize that these feature scores were calculated from different 
models (H: HGPIN model; G: GP3 model; P: GP4 model, D: DA model; C: Cribriform model). The 
reader should keep in mind that these feature matrices or scores don’t represent the findings for 
which DL models were trained and are results of feature extraction process in the deep layers of 
these models. 
After the feature maps were stored in the cMDX file format for all whole-slide images, the 
features scores were calculated and exported using custom tools for cMDX files as comma-
separated values (csv) files.  Later, we merged the clinicopathological information from the data 
hub of Xena browser (https://xenabrowser.net/hub/) and the csv file with features scores 
together by using the TCGA-PRAD case identification number. Finally, the genomic alterations, 
clusters, and subtypes introduced by the TCGA-PRAD study were considered for genomic 
analyses 4. 
Histogenomic Evaluation 
We identified 251 diagnostic H&E whole-slide images from TCGA-PRAD with available results for 
genomic alterations mentioned by the TCGA article.  We determined the importance of features 
extracted by our DL models by testing their association with the genomic alterations, clusters and 
subtypes introduced by the TCGA-PRAD study 4. Here, we evaluated the data distribution of 
feature scores and Gleason score in 30 genomic alterations and 5 subtypes and clusters 
mentioned in the TCGA study by applying non-parametric tests such as the Mann-Whitney test 
for binary classification, the Kruskal-Wallis Test for parameters with multiple classes, and the 
Pearson correlation test for two continuous values. Genomic alterations, subtypes, or clusters 
whose score distributions across their subgroups were not statistically identical at the 95% 
significance level were selected. For genomic alterations with unequal Gleason score 
distributions, the feature scores were stratified according to Gleason grading groups. Pirate plots 
were applied to illustrate the differences between categorical and continuous parameters. The 
odds ratios of the presence of categorized genomic alterations was estimated for each 
incremental increase of feature score using the logistic regression algorithm. The Area-under-the 
curve (AUC) and the corresponding 95% Confidence interval was evaluated for each feature score 
by the binary category of the genomic alteration. For subtypes or clusters with more than 2 
categories, we applied the Post-hoc test according to Tukey’s Honestly Significant Difference 
after ranking the feature scores. A difference was considered significance if its adjusted two-sided 
p-value (adj. P) according to Tukey was below 0.1. For all tests, with the exception of the post-
hoc and distribution analyses, the bootstrapping technique was applied to internal validation on 
1,000 samples 57. 
Prognostic Evaluation 
Biochemical Recurrence-Free Survival 
 
We identified 371 diagnostic FFPE H&E whole-slide images from TCGA-PRAD with follow-up for 
biochemical recurrence (BCR); BCR is defined by a consecutive rise of prostate-specific antigen -
PSA in at least two measurements or administration of adjuvant therapy for evidence of 
detectable PSA >0.1 ng/ml for at least 6 weeks postoperatively4,58.  
Univariate and multivariate cox regression analyses for BCR compromised H, G, P, C, and D 
feature scores. The Akaike information criterion (AIC) assessed the relative goodness-of-fit of the 
Cox regression models. We then applied stepwise cox regression to identify predictive variables 
that fit the cox regression model with the best relative goodness-of-fit. The variables from a cox 
regression model with the lowest AIC were selected for further analysis. Predictive accuracy 
estimates are generally quantified with concordance index. Two multivariable Cox regression 
models were developed. The first cox regression model (Model A) included the selected variables 
a and was fitted for BCR prediction.  The second cox regression model (Model B) contained the 
variables from Model A and the Gleason grading group. The linear predictor for BCR was 
estimated using these cox regression models. The linear predictor was then scaled between 0 
and 1 to define the prognostic score. The mean prognostic score was selected as cutoff to stratify 
the cohort into two groups. Kaplan-Meier plots illustrated BCR-free survival rates after 
stratification, according to tumor stage (pT), Gleason grading (Gls) and the binary prognostic 
score were generated. 
Cancer-specific Survival 
We applied the cox regression models for biochemical recurrence to predict cancer-specific 
survival (CSS) on two cohorts for external validation. The first cohort was adjusted to the 5-year 
CSS rate of 94% according to the survival data from Wright et al 25 and consists of 68 cases from 
McNeal’s dataset with a median follow-up of 9.4 years. The second cohort contained 125 
histology images from McNeal’s dataset with a median follow-up of 10.0 years. These cases were 
randomly selected. We chose one slide representing the index lesion identified by being the 
largest lesion in the prostatectomy specimens according to a graphical diagram representing the 
tumor distribution from each case 59. Further, we weighted cases with Gleason score 7a (3+4) 
and 7b (4+3) as cases with Gleason score 6 have a cancer-specific survival rate of 100% and it is 
clinically more important to stratify patients with higher Gleason scores according to their 
increased risk of cancer-associated death 60 and the CSS of Gleason score 7b was comparable to 
Gleason scores 8-1025. The steps to calculate and binarily categorize the prognostic scores were 
repeated for CSS as given in the previous section for BCR using the same cox regression model 
for BCR.  Kaplan-Meier-Curve was applied to illustrate the cancer-specific survival after 
stratification according to the low- and high-risk groups. 
Prognostic Evaluation  
The coefficient of significance for each variable of the cox regression was estimated using the 
Wald test. The global statistical significance of the cox regression model was evaluated using the 
likelihood-ratio test. The LR-test was applied to determine the best fitted model for BCR. We used 
the log-rank test to find significant differences between Kaplan Meier Curves. One-thousand 
bootstrap resamples were applied to reduce over-fitting bias and for internal validation. The 
proportional hazards (PH) assumption of the cox regression model was checked using statistical 
tests and graphical diagnostics based on the scaled Schoenfeld residuals. The reported p-value is 
two-sided and statistical significance was defined as P ≤ 0.05.  
Deep learning models and applied statistical Tools 
The detection analyses were based on Python 3.6 (Python Software Foundation, Wilmington, DE) 
and applied the Keras library which is built-on the TensorFlow framework, to develop the models. 
All analyses were performed on a GPU machine with 32-core AMD processor with 128 GB RAM 
(Advanced Micro Devices, Santa Clara, CA), 2 TB PCIe flash memory, 5 TB SDD Hard disks, and a 
single NVIDIA Titan V GPU with 12 GB VRAM. The statistical analyses were performed using R 
language and available packages for common statistical approaches and survival analysis (R 
Foundation for Statistical Computing, Vienna, Austria). 
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